Literature DB >> 31746434

Long non‑coding RNA HCP5 promotes prostate cancer cell proliferation by acting as the sponge of miR‑4656 to modulate CEMIP expression.

Renguang Hu1, Zhongjie Lu1.   

Abstract

Aberrant expression of long noncoding RNAs (lncRNAs) has been demonstrated in human cancers and regulates the malignant behavior of cancer cells. Previous studies demonstrated the critical involvement of lncRNA histocompatibility leukocyte antigen (HLA) complex P5 (HCP5) in the development of cancers, however, the function of HCP5 in prostate cancer has not been reported. In the present study, we found the overexpressed expression of HCP5 in prostate cancer tissues and cell lines via RT‑qPCR analysis. High expression of HCP5 was positively correlated with the metastasis of prostate cancer. Downregulation of HCP5 inhibited the proliferation, colony formation and induced apoptosis of prostate cancer cells. Functional experiments demonstrated that HCP5 acted as a competing endogenous RNA (ceRNA) to sponge miR‑4656. Ectopic expression of HCP5 decreased the expression of miR‑4656 in prostate cancer cells. MiR‑4656 was found to be decreased in prostate cancer tissues and was negatively correlated with the expression of HCP5. Further luciferase reporter assay revealed that miR‑4656 was able to bind the 3'‑untranslated region (3'‑UTR) of the cell migration inducing hyaluronidase 1 (CEMIP) and suppressed the expression of CEMIP. Consistent with the negative regulation of miR‑4656 by HCP5, western blot analysis uncovered that overexpression of HCP5 upregulated the abundance of CEMIP in prostate cancer cells. The CCK‑8 assay showed that depletion of CEMIP significantly inhibited the HCP5‑promoted proliferation of prostate cancer cells. Collectively, our data provide a novel mechanism by which HCP5 regulates the progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31746434     DOI: 10.3892/or.2019.7404

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  19 in total

1.  LncNAP1L6 activates MMP pathway by stabilizing the m6A-modified NAP1L2 to promote malignant progression in prostate cancer.

Authors:  Yuxiao Zheng; Feng Qi; Lu Li; Bin Yu; Yifei Cheng; Minghui Ge; Chao Qin; Xiao Li
Journal:  Cancer Gene Ther       Date:  2022-10-04       Impact factor: 5.854

2.  LncRNA DLX6-AS1 Promotes Malignant Phenotype and Lymph Node Metastasis in Prostate Cancer by Inducing LARGE Methylation.

Authors:  Zhifeng Zhao; Shuxia Liang; Fuguang Sun
Journal:  Front Oncol       Date:  2020-08-06       Impact factor: 6.244

3.  LncRNA HCP5 acts as a miR-128-3p sponge to promote the progression of multiple myeloma through activating Wnt/β-catenin/cyclin D1 signaling via PLAGL2.

Authors:  Qinhua Liu; Ruonan Ran; Mingyue Song; Xiaodan Li; Zhengsheng Wu; Guanrong Dai; Ruixiang Xia
Journal:  Cell Biol Toxicol       Date:  2021-07-31       Impact factor: 6.691

4.  Knockdown of Long Non-Coding RNA HCP5 Increases Radiosensitivity Through Cellular Senescence by Regulating microRNA-128 in Gliomas.

Authors:  Cuihong Wang; Guanying Yu; Ying Xu; Chengfei Liu; Qian Sun; Wenqing Li; Junhua Sun; Yuhua Jiang; Lan Ye
Journal:  Cancer Manag Res       Date:  2021-05-07       Impact factor: 3.989

5.  LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling.

Authors:  Jianyu Xu; Jianli Ma; Bixi Guan; Jian Li; Yan Wang; Songliu Hu
Journal:  Cell Cycle       Date:  2021-06-30       Impact factor: 5.173

6.  Knockdown of lncRNA HCP5 Suppresses the Progression of Colorectal Cancer by miR-299-3p/PFN1/AKT Axis.

Authors:  Ni Bai; Ying Ma; Jia Zhao; Bo Li
Journal:  Cancer Manag Res       Date:  2020-06-19       Impact factor: 3.989

7.  LncRNA ST8SIA6-AS1 promotes hepatocellular carcinoma cell proliferation and resistance to apoptosis by targeting miR-4656/HDAC11 axis.

Authors:  Qiang Fei; Feihong Song; Xinwei Jiang; Han Hong; Xiaoyong Xu; Zhengkang Jin; Xiang Zhu; Binghua Dai; Jiamei Yang; Chengjun Sui; Minhui Xu
Journal:  Cancer Cell Int       Date:  2020-06-11       Impact factor: 5.722

8.  MHC Class I Regulation: The Origin Perspective.

Authors:  Alicja Sznarkowska; Sara Mikac; Magdalena Pilch
Journal:  Cancers (Basel)       Date:  2020-05-04       Impact factor: 6.639

9.  LINC00861 inhibits the progression of cervical cancer cells by functioning as a ceRNA for miR‑513b‑5p and regulating the PTEN/AKT/mTOR signaling pathway.

Authors:  Hui Liu; Ling Zhang; Xiaoling Ding; Xuezuo Sui
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

10.  Signature Panel of 11 Methylated mRNAs and 3 Methylated lncRNAs for Prediction of Recurrence-Free Survival in Prostate Cancer Patients.

Authors:  Jiarong Cai; Fei Yang; Xuelian Chen; He Huang; Bin Miao
Journal:  Pharmgenomics Pers Med       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.